Martin-Achard A, Diserens A C, de Tribolet N, Zander E, Carrel S
Schweiz Med Wochenschr. 1978 Jun 24;108(25):959-62.
Anti-tumor antibodies have been searched for with an antibody-dependent cell-mediated cytotoxicity assay in the sera of patients with glioma. Sera from 60 patients and from 25 normal individuals have been tested against cells from 8 human glioblastoma lines. 10 patients (17%) and 5 controls (20%) were found to have antibodies against one or more tumor lines. There were extensive cross-reaction between the positive sera against the different glioma cells, but the reactivity of each serum was different. The specificity of the antibodies thus detected has been investigated. The positive patients' sera were found to have a similar cytotoxic activity against unrelated tumor and normal cells. Moreover, their activity was absorbed by cells from unrelated tumors and normal platelets. These results do not support the concept of a specific humoral response of glioma patients to a possible common tumor-associated antigen.
已采用抗体依赖的细胞介导的细胞毒性试验,在神经胶质瘤患者血清中寻找抗肿瘤抗体。对60例患者和25例正常个体的血清进行了检测,以检测其对8个人类胶质母细胞瘤细胞系的细胞的反应。发现10例患者(17%)和5例对照(20%)具有针对一种或多种肿瘤细胞系的抗体。针对不同神经胶质瘤细胞的阳性血清之间存在广泛的交叉反应,但每种血清的反应性不同。已对如此检测到的抗体的特异性进行了研究。发现阳性患者血清对无关肿瘤细胞和正常细胞具有相似的细胞毒性活性。此外,它们的活性被来自无关肿瘤的细胞和正常血小板吸收。这些结果不支持神经胶质瘤患者对可能的共同肿瘤相关抗原产生特异性体液反应的概念。